X
[{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences's Silmitasertib Receives Rare Pediatric Disease Designation from FDA for Treatment of Sonic Hedgehog Medulloblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences's Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences Presents Positive Cholangiocarcinoma Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pediatric Brain Tumor Consortium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pediatric Brain Tumor Consortium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa\u2019s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Senhwa Biosciences"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999 \\nS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"OBI Pharma"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"OBI Pharma"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OBI Pharma Announces Discontinuation of the Phase 1\/2 Study of its Antibody- OBI 888 To Focus on Other Priority Cancer Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"OBI Pharma"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targeting RAS: Golden Biotech Announces Positive Results with Longer Survival Compared with Standard Treatments from Interim Analysis of Phase 2 Trial for Antroquinonol as 1st Line Treatment for Stage 4 Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Golden Biotechnology"},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"National Health Research Institutes","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib\/II Protocol Amendment for ABT-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Anbogen Therapeutics"}]
Find Oncology Drugs in Phase I/II Clinical Development in TAIWAN
Filters
Details:
Hocena (antroquinonol) inhibits Ras and Ras-related GTP-binding protein activation and is being investigated in combination with the standard of care nab-paclitaxel plus gemcitabine for first-line treatment of metastatic pancreatic cancer.
Lead Product(s):
Antroquinonol ,Paclitaxel ,Gemcitabine
Therapeutic Area: Oncology
Product Name: Hocena
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 05, 2023
Details:
ABT-101 (DBPR112) demonstrates excellent therapeutic potential and superior safety profile compared to competitors that are under clinical development. It meets challenges of unmet medical needs for cancer drugs targeting exon 20 insertions in HER2.
Lead Product(s):
DBPR112
Therapeutic Area: Oncology
Product Name: ABT-101
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
National Health Research Institutes
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 13, 2022
Details:
A first in class monoclonal antibody cancer immunotherapy, OBI-888 targets Globo H, antibody, a glycolipid antigen expressed in up to 15 epithelial cancers.
Lead Product(s):
OBI-888
Therapeutic Area: Oncology
Product Name: OBI-888
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 05, 2022
Details:
OBI-999, uses Globo H antibody to recognize the cancer cells with high Globo H expression and releases the active drug to prevent tumor growth and kill tumor cells.
Lead Product(s):
OBI-999
Therapeutic Area: Oncology
Product Name: OBI-999
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 17, 2022
Details:
USFDA has granted Orphan drug designation for CX-4945 (silmitasertib), a highly selective inhibitor of casein kinase 2, on the basis of significant results from pre-clinical studies which demonstrate DNA repair and induce apoptosis in patients with Biliary Tract Cancer.
Lead Product(s):
Silmitasertib ,Cisplatin ,Gemcitabine
Therapeutic Area: Oncology
Product Name: CX-4945
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 20, 2022
Details:
Silmitasertib, a treatment for Medulloblastoma, a severe pediatric disease for which there are no approved therapies. ODD represents an important regulatory milestone that has the potential for the clinical development of Silmitasertib, a potent and selective CK2 inhibitor
Lead Product(s):
Silmitasertib
Therapeutic Area: Oncology
Product Name: CX-4945
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Pediatric Brain Tumor Consortium
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 17, 2021
Details:
Senhwa’s clinical partner, the Pediatric Brain Tumor Consortium, is currently conducting a Phase I/II and Surgical Study of Silmitasertib in both children and adults with recurrent SHH Medulloblastoma.
Lead Product(s):
Silmitasertib
Therapeutic Area: Oncology
Product Name: CX-4945
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Pediatric Brain Tumor Consortium
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 17, 2021
Details:
The study met its primary endpoint during an interim analysis by demonstrating a statistically significant difference in the Silmitasertib plus Gemcitabine and Cisplatin Arm.
Lead Product(s):
Silmitasertib ,Cisplatin ,Gemcitabine
Therapeutic Area: Oncology
Product Name: CX-4945
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 15, 2021
Details:
Senhwa was invited to present positive topline results from their global phase II trial, evaluating the combination of Silmitasertib plus Gemcitabine/Cisplatin compared to Gemcitabine/Cisplatin alone in the frontline treatment of patients with Cholangiocarcinoma.
Lead Product(s):
Silmitasertib ,Gemcitabine ,Cisplatin
Therapeutic Area: Oncology
Product Name: CX-4945
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 13, 2020
Details:
U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for company's drug Silmitasertib, a Casein Kinase 2 (CK2) inhibitor, being developed as a treatment for recurrent sonic hedgehog (SHH) medulloblastoma.
Lead Product(s):
Silmitasertib
Therapeutic Area: Oncology
Product Name: CX 4945
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 07, 2020